A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

About UMGCC

2013-2014 Fact Sheet

Overview:

The University of Maryland Marlene and Stewart Greenebaum Cancer Center is a National Cancer Institute-designated cancer center and one of the top cancer treatment and research centers in the country. As part of the University of Maryland Medical Center, we offer innovative approaches to diagnosing and treating all types of cancer; conduct cutting-edge research to bring the latest advances in cancer treatment directly to our patients; and provide cancer screening and patient education services.

Outstanding Patient Care & Scientific Excellence:

  • A team approach to care where specialists from all cancer disciplines work together to develop an individualized treatment plan for each patient
  • Minimally invasive treatment options, including stereotactic body radiation therapy, robot-assisted surgery and the newest, targeted drug therapies
  • Innovative clinical trials offering patients promising new therapies, often years before they are available commercially
  • Patient-focused treatment environment, including the Stoler Pavilion for outpatient cancer care, with dedicated pharmacy and infusion center, and private rooms for all inpatients
  • An active translational research program, with experts leading major advances in cancer research, including development of cancer vaccines, new technologies, novel cancer-fighting agents and promising combination therapies
  • Top-rated nursing staff specially trained in cancer care and consistently rated outstanding in patient satisfaction surveys
  • Support services, including social work, patient navigators, genetic and nutrition counseling, image renewal center and acupuncture for cancer symptom management
  • Education, outreach and free cancer screenings for underserved citizens through the Baltimore City Cancer Program
  • Partnerships with a network of community hospitals allowing residents throughout Maryland to benefit from specialized cancer expertise and clinical trials close to home

Our National Profile:

Quick Numbers
Outpatient Visits 66,667
Inpatient admissions 2,151
New patient annually 2,559
Clinical trials 213
Physicians and researchers 247
Research funding $64.2M
  • UMGCC is a National Cancer Institute (NCI)-Designated Cancer Center, a distinction shared by only 68 centers across the U.S.
  • UMGCC is ranked among the top cancer programs in the country, according to U.S. News & World Report's Best Hospitals list.
  • Cancer research funding at UMGCC has grown dramatically since 2002 – from $19.4 to $64.2 million, continuing to drive scientific discovery by our cancer experts, all of whom are on the faculty of the University of Maryland School of Medicine.
  • UMGCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities, who represent 36 percent of the patients in our clinical trials, compared to less than 2 percent nationally.
  • The Maryland Proton Treatment Center, opening in 2015 in the University of Maryland Biopark, is a next-generation radiation treatment facility expected to treat 2,000 cancer patients per year when fully operational.
  • Dr. Stuart Martin discovered that microtentacles” on breast cancer cells play a key role in how cancers spread in the body.
  • Dr. Angela Brodie discovered aromatase inhibitors for the treatment of breast cancer. Recent trials also showed that these drugs can prevent two thirds of cancers in women at high risk for developing the disease. Dr. Brodie and her colleagues have developed a new androgen synthesis inhibitor that shows great promise in treating prostate cancer
  • Dr. Kevin Cullen's research demonstrated for the first time that racial survival disparities in head and neck cancer are largely explained by previously unknown differences between racial and ethnic groups in the rate of human papillomavirus (HPV) infection.
  • UMGCC researchers are pioneering stem cell and HIV/AIDS–related cancer studies in partnership with the University of Maryland Center for Stem Cell Biology and Regenerative Medicine and the Institute of Human Virology.
Dr. Stuart Martin's discovery of microtentacles

Dr. Stuart Martin's discovery of microtentacles on circulating tumor cells may help scientists develop ways to prevent metastasis. Here, two breast cancer cells attach to each other. The cell on the left expresses a green fluorescent protein (GFP) that makes it possible to see how its microtentacles encircle the red adjacent cell.

Cancer Treatment Specialties


This page was last updated on: May 9, 2014.